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Epigenetic Control of MAGE Gene Expression
by the KIT Tyrosine Kinase
Bing Yang1, Jianqiang Wu1, Nityanand Maddodi1, Yongsheng Ma1, Vijayasaradhi Setaluri1
and B. Jack Longley1
The Class I MAGE proteins include the MAGE-A, MAGE-B, and MAGE-C antigens, which are normally expressed
only in male germ cells but may be aberrantly expressed in melanomas and other tumors. It is known that MAGE
gene expression is epigenetically repressed by promoter region methylation in most cells but factors
controlling MAGE gene promoter methylation have not been identified. Using transcript microarray analysis
and immunoblotting we found that MAGE-A and MAGE-C mRNA and protein are selectively downregulated by
pharmacologic inhibition of KIT in KIT-dependent mast cell lines. Methylation-specific polymerase chain
reaction studies showed that the MAGE-A3 and MAGE-C2 gene promoter regions were de-methylated in the
presence of activated KIT but became methylated on inhibition of KIT, consistent with the downregulation of
mRNA and protein. This is early evidence of a tyrosine kinase affecting MAGE gene promoter region
methylation and expression, and represents early evidence of a tyrosine kinase in the epigenetic control of
gene expression. MAGE proteins suppress apoptosis and promote tumor survival, and are novel targets for
functional manipulation and immunotherapy. Understanding the factors controlling MAGE gene expression
may allow more effective therapeutic strategies targeting MAGE antigens.
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INTRODUCTION
The MAGE-A, MAGE-B, and MAGE-C families comprise the
Class I MAGE genes (Simpson et al. , 2005). Class I MAGE
genes are normally expressed only in developing cells of the
spermatogenic series but are of general interest because they
may be aberrantly expressed in melanomas and other
malignancies (Knuth et al., 1989; Jungbluth et al., 2000). It
has been established that MAGE gene expression is sup-
pressed by methylation of critical CpG dinucleotide islands in
the MAGE gene promoter regions (De Smet et al., 1999;
Sigalotti et al., 2004), but other factors besides promoter
region hypomethylation are necessary for expression (Karpf
et al., 2004). Unlike most genes, the promoter regions of
Class I MAGE genes are normally methylated and MAGE
gene expression is repressed in all cells except male germ
cells. It is interesting that these cells also express the KIT
tryosine kinase (Strohmeyer et al., 1995).
Recently, while studying downstream signaling pathways of
the KIT tyrosine kinase, we noted that KIT-dependent mast cell
lines express Class I MAGE genes, and that their expression
suppresses apoptosis (Yang et al., 2007). Here, we show that
inhibition of the KIT kinase in these cells results in down-
regulation of MAGE gene mRNA, methylation of MAGE gene
promoters, and suppression of MAGE protein expression. These
findings identify a novel mechanism of KIT signal transduction
and, to our knowledge, represent the first demonstration of
epigenetic control of a gene by a tyrosine kinase.
RESULTS
Inhibition of KIT downregulates MAGE gene expression
Human malignant mast cell line (HMC1) expresses mutated,
constitutively active KIT that drives cell proliferation and
prevents apoptosis (Ma et al., 2002). HMC1.1 and HMC1.2
are two subclones of HMC1 that express KIT mutations,
which differ in their sensitivity to a clinically useful KIT
tyrosine kinase inhibitor called ‘‘Imatinib.’’ HMC1.1 ex-
presses KIT with a codon 560 substitution that disrupts an
intracellular juxtamembrane auto inhibitory region, thereby
activating the KIT kinase without changing the structure of the
kinase enzymatic site. In contrast, HMC1.2 expresses KIT
with a codon 816 mutation that alters the activation loop of
the kinase enzymatic site. The mutated KIT expressed by
HMC1.1 is sensitive to inhibitors of wild-type kinases like
Imatinib, whereas the mutated KIT expressed by HMC1.2 is
resistant to Imatinib (Figure 1).
Class I MAGE genes are coordinately downregulated during
KIT-dependent apoptosis
To identify genes involved in KIT regulation of growth and
survival, we used mRNA array analysis to compare gene
expression levels in HMC1.1 and HMC1.2 before and after
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treatment with Imatinib. As we expected, we found that
treatment of the Imatinib-sensitive HMC1.1 cell line induced
significant changes in expression of a large number of genes
(499), most of which are associated with cell growth and
maintenance; there were changes in the expression of genes
controlling growth factor response, signal transduction, and
phosphate metabolism (Table 1). Treatment of HMC1.2, which
expresses mutation-activated KIT that is resistant to Imatinib,
showed almost no effect following treatment with Imatinib,
indicating remarkable specificity of the drug in these cells. No
genes changed more than twofold and only 25 of 22,000
showed changes between one- and twofold, compared with
499 genes in this range for the Imatinib-sensitive HMC1.1 cell
line. Furthermore, none of the 25 genes in the 1–2-fold range in
HMC1.2 match those that change in HMC1.1, indicating that
they are unlikely to represent an effect of the drug but more
likely represent chance effects seen when significance tests are
applied to 22,000 genes, despite using the Bonferroni
correction. Subtracting the ‘‘noise’’ of 25 genes in HMC1.2
from the 499 genes in HMC1.1 still leaves 474 genes with
significant change in the Imatinib-sensitive HMC1.1 line.
In reviewing the microarray data, we had noticed that both
mast cell lines expressed transcripts for multiple Class I
MAGE family proteins, a novel observation (Yang et al.,
2007). Interestingly, we also noted that expression of many
MAGE family mRNAs was downregulated in the sensitive
HMC1.1 line as early as 4 hours after induction of apoptosis
by Imatinib, but MAGE mRNA expression was not changed
by Imatinib in the resistant HMC1.2 cell line (Table 2).
Immunoblotting of HMC1.1 and HMC1.2 whole cell lysates
from before and at 12 and 24 hours after treatment with
Imatinib showed regulation of MAGE family proteins in
HMC1.1 but not HMC1.2 cells, confirming the physiologic
significance of the mRNA array data (Figure 2). Note that the
array analysis experiments were designed to detect the
earliest changes in gene expression after KIT inhibition and
the decreases in MAGE mRNA levels in the early stages of
response to Imatinib are small but statistically significant. The
biologic relevance of these changes, however, is confirmed
by the dramatic drop in protein at the later time points.
KIT inactivation causes MAGE-A3 and MAGE-C2 promoter
region methylation
As MAGE-A3 is the MAGE antigen most commonly expressed
in human malignancies, we focused on it as representative of
the MAGE-A family proteins. We also studied MAGE-C2, as it
was the only other Class I MAGE gene with significant
expression in HMC1.1 cells (Table 2 and Figure 2). It is
known that hypermethylation of specific promoter region
CpG dinucleotide islands suppresses expression of MAGE-A3
and MAGE-C2 (De Smet et al., 1999; Furuta et al., 2004;
Wischnewski et al., 2006), so we used methylation-specific
polymerase chain reaction to determine the effects of KIT
inhibition on CpG island methylation in these promoter
regions. The first row of Figure 3 shows that the MAGE-A3
promoter region is normally hypomethylated in both the
HMC1.1 and HMC1.2 cell lines, and that inhibition of KIT by
HMC-1.1
Anti-pTyr
Anti-KIT
HMC-1.2
0 10.1 0 10.1Imatinib (M)
Figure 1. Imatinib inhibits KIT-phosphorylation in HMC-1.1 cell line
but not the HMC-1.2 cell line. Immunoprecipitation with anti-KIT and
immunoblotting with anti-phosphotyrosine antibody (anti-PY) shows the regulatory
type mutant-activated KIT in HMC1.1 is inhibited by Imatinib but the enzymatic
site type mutant KIT expressed in the HMC1.2 cell line is resistant to Imatinib.
Table 1. Genes that are significantly regulated in
HMC.1.1 and HMC1.2 cells by the KIT inhibitor
Imatinib
42-fold 1ofoldo2
Gene class HMC1.1 HMC1.2 HMC1.1 HMC1.2
Molecular function (Gene Ontology)
RNA helicase 4
Cyclin 3
Chaperone 7
Mitochondrion 14
Oxidative phosphorylation 5
Phosphate metabolism 4 0 15
Cell growth and/or
maintenance
6 0 116
Oligosaccharyl transferase
complex
2
Primary active transporter 12
Protein kinase activator 3
Biological process (Protein domain)
Hsp70 protein 4
Src homology domain 2 7
Ras family 10
ATP synthase subunit C 2
MAGE family 6
Cell division protein FtsA 3
Cellular component
Cytoband 51
Signal transduction 7 0
Glycogen Catabolism 1
Protein assembly 2
Metabolism 7
Atrial natriuretic peptide 1
In HMC1.1 cells, 499 genes showed 41-fold change in median
expression and 17 genes showed 42-fold change. In HMC1.2 cells, only
25 genes showed41-fold change and none showed42-fold change. The
genes listed were classified according to overlapping categories including
molecular function and biological processes, and some genes are
included in more than one category, so the total numbers are not the
actual numbers of changed genes. *Indicates Pp0.05 compared with
untreated cells.
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Imatinib in HMC1.1 causes methylation of the MAGE-A3
promoter. In contrast, there is no change in MAGE-A3
promoter region methylation in HMC1.2, which expresses
activated KIT that is resistant to Imatinib. The second row of
Figure 3 shows similar results with the MAGE-C2 promoter
except that inhibition of KIT results in a heterogeneous
pattern of methylation in HMC1.1, so that both methylated
and unmethylated MAGE-C2 promoter region DNA are
detected in Imatinib-treated HMC1.1 cells. This last result is
not surprising given that heterogeneous patterns of MAGE
promoter region methylation have previously been observed
in melanoma cell lines (Furuta et al., 2004; Sigalotti et al.,
2004). In HMC1.1 cells, this pattern correlates with a
significant decrease in MAGE-C2 mRNA and protein
(Figure 2). In contrast, treatment with Imatinib has no
significant effect on MAGE-C2 promoter methylation in the
Imatinib-resistant HMC1.2 cell line, indicating that activated
KIT can maintain MAGE promoter regions in a hypomethy-
lated state, thereby contributing to control of MAGE protein
expression. This experiment serves as an important control for
our results with the HMC1.1 cell line because although it
appears that additional factors downstream of promoter
methylation affect MAGE-C2 mRNA and protein expression
in HMC1.2 cells, our observations with HMC1.2 cells show
that the changes in promoter region methylation are only
seen when KIT is affected and are not a non-specific effect of
Imatinib.
DISCUSSION
Understanding mechanisms controlling MAGE gene expres-
sion is of interest because MAGE proteins may contribute to
the development of melanomas and other malignancies, and
to their resistance to cytotoxic agents (Dhodapkar et al.,
2003; Duan et al., 2003; Monte et al., 2006; Yang et al.,
2007). In addition, because MAGE protein expression is
normally limited to developing male germ cells, MAGE
proteins have served as tumor-specific antigens in a number
of immunotherapeutic strategies including some involving
manipulation of MAGE gene expression (De Smet et al.,
1999; Park et al., 1999; Coulie et al., 2002).
A number of studies have identified expression of the Class
I MAGE proteins A1, A3, and A4 in prenatal human
gonocytes, prespermatogonia, and spermatocytes (Takahashi
et al., 1995; Gaskell et al., 2004) and expression of MAGE-C
proteins has been shown in adult testicular germ cells
(Jungbluth et al., 2002). The basis for this tissue-specific
Table 2. KIT-dependant mast cell lines express MAGE-A and MAGE-C mRNAs, which are downregulated in
HMC1.1 within 4 h after inhibition of KIT
Gene description
Actual value
% Change
(downregulation) Actual value
% Change
(downregulation)
Untreated HMC1.1
(mean7SD)
Imatinib-treated
HMC1.1 (mean7SD) HMC1.1
Untreated HMC1.2
(mean7SD)
Imatinib-treated
HMC1.2 (mean7SD) HMC1.2
MAGE-A1 35427209 29627139* 16.371.2* 39487296 36657743 NC
MAGE-A3 92277845 74137183* 9.375.9* 1972672063 1859973252 NC
MAGE-A5 21997339 18307249* 16.674.6* 3530750 34397560 NC
MAGE-A6 75457455 56767697* 24.975.4* 1533571871 1571671473 NC
MAGE-A12 57247408 48537386* 15.370.7* 74987331 732571184 NC
MAGE-C 2 22487232 14807151* 34.70.1* 4277231 5137185 NC
MAGE mRNAs are not downregulated in the HMC1.2 cell line, which expresses inhibitor-resistant KIT. Note that significant MAGE-B mRNA is not expresses
in either cell line and that only very low levels of MAGE-C2 mRNA are expressed by the HMC1.2 cell line. Differences between pre- and posttreatment
MAGE mRNAs in HMC1.1 are significant by t-test, Po0.05, and are indicated by *. Differences between MAGE mRNA levels in HMC1.2 pre- and
posttreatment are not significant and are indicated as no change (NC). Actual values and significant percentage changes are shown as (%) mean7SD.
HMC-1.1 HMC-1.2
0 12 hours 24 hours 12 hours 24 hours0Imatinib
MAGE-A
MAGE-B2
MAGE-C2
Blot
-Actin
Figure 2. Imatinib downregulates MAGE protein expression in sensitive
HMC1.1 cell line but not in HMC1.2 which expresses Imatinib resistance.
Immunoblotting shows MAGE-A and MAGE-C proteins are downregulated in
HMC1.1 cells at 12 and 24 hours after induction of apoptosis by Imatinib, but
not downregulated in the Imatinib-resistant HMC1.2 cell line. Note that no
significant expression of MAGE-B protein is identified. Note also that the
HMC1.2 cell line does not express detectable MAGE-C2 protein, in
agreement with the very low levels of MAGE-C2 mRNA seen in this cell line.
HMC-1.1 HMC-1.2
– –+ +
U M U M U M U M
Imatinib
MAGE-A3 promoter
MAGE-C2 promoter
Figure 3. KIT inhibition affects methylation of MAGE-A3 and MAGE-C2
promoters in Imatinib sensitive human mast cells. Methylation-specific PCR
amplification of MAGE promoter regions from DNA extracted before or after
addition of Imatinib, which inhibits activated KIT in the HMC1.1 mast cell
line but not the HMC1.2 subclone. Each band confirms the presence of target
DNA that is either unmethylated (U) or methylated (M).
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regulation has not been previously established, but our data
suggest that expression of activated KIT may allow MAGE
gene expression by suppressing the methylation of MAGE
promoter regions that is normally found in all tissues besides
the testes. In support of this hypothesis is the fact that all cells
of the spermatogenic series in adult testes express both KIT
and MAGE proteins up through meiosis (Sandlow et al.,
1997; Yin et al., 1998; Jungbluth et al., 2000, 2002). Thus,
expression of Class I MAGE proteins is temporally and
spatially associated with expression of KIT in testes, support-
ing the hypothesis that KIT activation may contribute to
normal tissue-specific regulation of MAGE proteins.
A normal function for MAGE proteins is suggested by the
facts that expression of select MAGE proteins prevents
p53-mediated apoptosis (Monte et al., 2006; Yang et al.,
submitted) and that p53 expression is critical for normal
spermatogenesis (Yin et al., 1998; Monte et al., 2006; Yang
et al., 2007). For instance, p53/ mice show decreased germ
cell apoptosis, an increased percentage of morphologically
abnormal sperm, and reduced fertility, suggesting that
p53-dependent cellular proofreading maintains the integrity
of male germ cells during spermatogenesis. Loss of PI3-K
binding by the KIT mutant Y719F results in a 90% reduction
in AKT activation, but mice homozygous for this mutant have
normal mast cells and melanocytes (Blume-Jensen et al.,
2000), probably because of redundancy of KIT-dependent
pathways that activate proliferation. However, male but not
female kitY719F homozygotes are sterile owing to extensive
apoptosis occurring at the spermatogonial stem cell level,
indicating a failure of the mutant KIT to suppress apoptosis.
Interestingly, male mice homozygous for the kitWv loss of
function mutation have decreased germ cell viability and are
infertile, but this defect is rescued in double-mutant
p53/ kitWv/Wv mice, indicating that KIT may normally
protect developing male germ cells by suppressing a
p53-dependent apoptotic pathway (Jordan et al., 1999). KIT
also appears to be relevant to human fertility as decreased
KIT expression is seen in testes of subfertile adult humans,
and is associated with increased apoptosis in spermatocytes
(Feng et al., 1999). We have recently shown that MAGE
proteins suppress p53 expression and apoptosis (Yang et al.,
2007; Yang et al., submitted), and we speculate that the
normal function of MAGE genes may be to selectively
suppress a p53-dependent ‘‘mitotic catastrophe’’ response
during meiosis and that MAGE genes may represent
mammalian equivalents of the germ line apoptosis genes
involved in the maintenance of genomic stability and fertility
in male germ cells.
Unlike developing male germ cells, normal human
cutaneous mast cells and melanocytes do not express MAGE
proteins (Jungbluth et al., 2000). The reason for this is not
clear but it probably involves cell-specific transcription
factors since demethylation of normal cultured human
melanocytes does not cause MAGE gene expression (Karpf
et al., 2004). As alternative KIT signaling pathways involving
MiTF and BCL2 are available to promote survival, it appears
that the MAGE pathway is not required by normal cutaneous
mast cells and melanocytes.
Epigenetic inheritance is a reversible heritable change in
gene function or other cell phenotype that occurs without a
change in the DNA sequence. Promoter region methylation
can be passed on from one generation of a cell to the next
and is a major mechanism of epigenetic control of gene
expression. It is known that MAGE gene expression is
primarily repressed epigenetically by promoter region
methylation and that MAGE genes are unusual because they
are heavily methylated in all normal tissues except the testes.
KIT activation is probably not required for MAGE gene
expression in most tumors, as the global demethylation that
often occurs with tumor progression may cause demethyla-
tion of MAGE promoters independent of KIT expression (De
Smet et al., 1999). However, our data show that KIT
activation can prevent MAGE gene promoter region methyla-
tion in the proper cellular context and our studies establish a
mechanism for tissue-specific regulation of MAGE gene
expression. Further delineation of this mechanism will be
important, and work published by Tsai et al. (2006) while this
paper was under revision offers a clue to potential
components of this pathway. These investigators found that
DNA methyltransferase-1 activation by the Epstein–Barr virus
protein LMP1 required functional June-terminal kinase (JNK).
Because JNK is a downstream mediator of KIT, JNK is an
attractive target for additional study.
It has long been recognized that the limited tissue
distribution of MAGE proteins provides an opportunity for
tumor-specific treatment of many different malignancies
(Strohmeyer et al., 1995; Coulie et al., 2002), and accumulat-
ing data suggest that aberrant expression of MAGE protein
may allow malignant cells to stave off mitotic catastrophe
induced by abnormal replication or cytotoxic agents. Under-
standing how MAGE protein expression can be controlled
will allow more sophisticated strategies for treatment of
MAGE-positive melanomas and other malignancies.
MATERIALS AND METHODS
Reagents, buffers, and cells
Iscove’s media for cell culture was purchased from Cellgro
(Midatech Inc, Herndon, VA). Trizol reagent and SuperScript choice
system were from Invitrogen (Grand Island, NY). Pheno/chloroform/
isoamyl alcohol was from Ambion (Austin, TX). Rneasy Minikit was
from Qiagen Inc. (Valencia, CA). RNA Transcript labeling Kit was
from Enzo Diagnostics (Farmingdale, NY). Affymetrix HU133A
genechips were purchased from Affymetrix (Santa Clara, CA).
Two subclones of the human mast cell leukemia line HMC1 were
used for this study. The HMC1.1 subclone expresses a valine to
glycine substitution in codon 560 (Val560Gly) of the KIT intracel-
lular juxtamembrane region. The HMC1.2, subclone expresses the
Val560Gly mutation and a second substitution, aspartate to valine in
codon 816 (Asp816Val) in the kinase enzymatic site. Cells were
grown in Iscove supplied with 10% heat-inactivated fetal bovine
serum, 0.01% monothioglycerol at 371C under 5% CO2 in a
humidified atmosphere.
Treatment of HMC1 cells with Imatinib
The dose and incubation times were pretested to ensure that
KIT activity in HMC1.1 cells was completely inhibited (data not
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shown). Imatinib (Novartis, New York, NY) or phosphate-
buffered saline was added directly to 2 107 HMC1 cells and
incubated for 4 hours. A total of 5 106 cells were used for Western
blot analysis, and RNA was isolated from the rest for microarray
analysis.
Microarray probe preparation
Total RNA was extracted using Trizol reagent and cleaned with the
Rneasy Mini Kit according to the manufacturer’s instructions. Briefly,
10 mg of total RNA was reverse-transcribed into double-stranded
cDNA using a (deoxythymidine)-24 primer containing a
T7 polymerase promoter (Genet, La Jolla, CA). cDNA was purified
and used for in vitro transcription in the presence of biotinylated
UTP and CTP using the BioArray high-yield RNA transcript labeling
Kit. Biotinylated cRNA was purified and qualified by agarose gel and
spectrophotometery (260 nM/280 nMX1.8). The cRNAs were then
heat-fragmentated at 941C for 35 minutes and stored at 201C until
hybridization.
Hybridization and scan
Fifteen micrograms of fragmentated, biotinlytaed cRNA were
hybridized with the affymetrix arrays at 451C for 16 hours, and
then washed and stained by using the Genechip Fluidics station.
The arrays were scanned with the GeneArray scanner (Affymetrix),
and the fluorescence images obtained were processed by the
expression analysis algorithm in Affymetrix Microarray Suite
(MAS), version 5.0.
Data analysis
MAS.CEL. files were converted into .DCP files using dCHIP (http://
www.dchip.org), as described previously by Li and Wong (Genome
Biol 2001, 2:RESEARCHH0032). The DCP files were normalized,
and raw gene expression data were generated using the dCHIP
system of model-based analysis. For comparison of gene expression
profiles between Imatinib-treated and control HMC1.1 cells, a two-
pronged strategy was used. The first comparison was performed
using dCHIP software itself, where the control cells were designated
as baseline, and the Imatinib-treated cells were designated as
experiment; three independent replicates were used. Genes altered
over 1 (or 2)-fold in the Imatinib-treated versus control groups were
then identified by defining the appropriate filtering criteria in the
dCHIP software (mean E(Imatinib treated cells)/mean B (control
cells)41- or 2-fold; mean Emean B4100, Po0.05, t-test). We first
chose a low onefold threshold to get the global gene expression
patterns induced by Imatinib, and twofold change to get specifically
regulated genes. A second comparison was performed using
RBioconductor. Genes in the intersection of the two methods of
data analysis were considered as potential molecular targets of
Imatinib. Hierarchical clustering of gene expression profiles was
performed using Pearson’s correlation with a threshold of Po0.005
for significant clusters. For hierarchical clustering of experimental
samples, Pearson’s correlation was used at a threshold of Po0.05 for
significant clusters. Finally, visual inspection of microarray data was
used to search for genes relevant to KIT, mast cell, or melanocyte
biology which showed significant change that was below the
onefold threshold. The six MAGE genes listed in Table 2 were
identified from the intersection of data sets from dCHIP and
R-Bioconductor.
Immunoblotting
MAGE protein expression was determined by immunoblotting of
whole cell lysates using standard techniques. The antibodies we
used for MAGE are pan-MAGE-A (monoclonal, Zymed, South San
Francisco, CA), anti-MAGE-B2 (polyclonal, Santa Cruz Biotechnol-
ogy, Santa Cruz, CA), or anti-human MAGE-C2 (monoclonal, kindly
supplied by Ludwig Institute for Cancer Research, New York, NY).
For KIT phosphorylation, cells lysates were immunoprecipitated with
mouse anti-c-KIT monoclonal antibody (Santa Cruz Biotechnology),
electrophoresis in polyacrylamide gel with SDS, immunoblotting
with antiphosphotyrosin antibody (Upstate, Lake Placid, NY), then
stripped and reprobed with anti-c-KIT antibody as described
previously (Wischnewski et al., 2006).
Bisulfite modification
Genomic DNA (1mg) was denatured in 0.3 M NaOH at 371C for
10 minutes. Sulfonation and de-amination of DNA was performed by
incubating for 16 hours at 551C with sodium bisulfite solution
(Chemicon, Billerica, MA). Modified DNA was desalted and purified
with the Wizard DNA purification kit (Promega, Madison, WI) and
desulfonated in 0.3 M NaOH at 371C for 5 minutes. DNA was
purified with Wizard DNA purification kit and eluted in 30 ml sterile
water and performed methylation-specific PCR (MSP) using specific
methylated (M) and unmethylated (U) primers for MAGE-A3 and
MAGE-C2.
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